Group One Trading
VTGN icon

Group One Trading’s VistaGen Therapeutics VTGN Stock Holding History

Group One Trading’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-54,300
Closed -$35.9K – 8863
2025
Q4 		$35.9K Buy
54,300
+53,800
+10,760% +$194K ﹤0.01% 5871
2025
Q3 		$1.77K Buy
500
+100
+25% +$299 ﹤0.01% 7933
2025
Q2 		$800 Hold
400
– – ﹤0.01% 7601
2025
Q1 		$1K Sell
400
-209,000
-100% -$592K ﹤0.01% 7178
2024
Q4 		$618K Buy
209,400
+40,000
+24% +$113K ﹤0.01% 2994
2024
Q3 		$510K Buy
169,400
+149,400
+747% +$510K ﹤0.01% 2850
2024
Q2 		$69.6K Sell
20,000
-6,600
-25% -$28.6K ﹤0.01% 4263
2024
Q1 		$140K Buy
26,600
+3,000
+13% +$14.4K ﹤0.01% 3846
2023
Q4 		$121K Sell
23,600
-12,400
-34% -$46.9K ﹤0.01% 4296
2023
Q3 		$189K Buy
+36,000
New +$160K ﹤0.01% 3855
2022
Q4 		– Sell
-253
Closed -$1K – 8166
2022
Q3 		$1K Buy
253
+20
+9% +$198 ﹤0.01% 7391
2022
Q2 		$6K Buy
+233
New +$8.23K ﹤0.01% 7039

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Group One Trading's VTGN Position: Q1 2026 in Review

Group One Trading reduced its VistaGen Therapeutics (VTGN) stake by 81% in Q1 2026, selling an estimated $52.4K and leaving 19,875 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6307.

Group One Trading first reported a position in VTGN in Q2 2022 and has held it in 12 quarters since. The position peaked at $395K in Q3 2023. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Group One Trading held 19,875 shares of VistaGen Therapeutics worth $11.4K as of Q1 2026.
  • Group One Trading sold 86,262 VistaGen Therapeutics shares in Q1 2026, an estimated $52.4K.
  • VistaGen Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6307 holding.
  • Group One Trading first reported a position in VistaGen Therapeutics in Q2 2022 and has held it in 12 quarters since.
  • Group One Trading's VistaGen Therapeutics position peaked at $395K in Q3 2023.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.